Repligen (RGEN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$785.1M

Revenue (quarter)

$204.1M

Revenue growth (year over year)

+11.93%

Gross profit (trailing twelve months)

$420.2M

Gross margin

53.52%

Net income (trailing twelve months)

$41.5M

Net income (quarter)

$5.0M

Net income growth (year over year)

−66.31%

Net margin

5.29%

Return on equity

1.99%

EPS (trailing twelve months)

$0.74

Book value per share

$37.43

P/E (trailing twelve months)

216.45

Price to book

4.26

Debt to assets

28.41%

Payout ratio

—

Dividend yield

—

Company profile

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

• Is Repligen (RGEN) profitable?

  Yes. Repligen earned $41.5M in net income over the trailing twelve months, a net margin of 5.29%.

• How much revenue does Repligen (RGEN) make?

  Repligen generated $785.1M in revenue over the trailing twelve months, up 11.93% year over year.

• What is RGEN's P/E ratio?

  Repligen trades at 216.5 times trailing twelve-month earnings, on an EPS of $0.74.

• How do I buy stock in Repligen (RGEN)?

  RGEN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.